Payers are more interested in effectiveness rather than efficacy of novel treatments. In light of health economics, cost-effectiveness is preferred

More and more potentially curative interventions become available in oncology. Thus, a growing proportion of cancer patients might indeed be

Due to immaturity of survival data in clinical trials at time of health technology assessment, long-term predictions of survival result